Robin K. Dore

TL;DR: Teriparatide, a bone formation agent, increased BMD at most sites and decreased nonvertebral fractures more than alendronate in 146 postmenopausal women with osteoporosis.

TL;DR: Therapy with cevimeline, 30 mg 3 times daily, seems to be well tolerated and to provide substantive relief of xerostomia symptoms, although both dosages provided symptomatic improvement, 60 mg3 times daily was associated with an increase in the occurrence of adverse events, particularly gastrointestinal tract disorders.

TL;DR: In this article, 30 mg of cevimeline, 3 times daily, was used for the treatment of xerostomia, and the drug was generally well tolerated with expected adverse events resulting from the drug's muscarinic agonist action.

TL;DR: Patients randomized to teriparatide had a reduced risk of new or worsening back pain compared to patients randomized to placebo, hormone replacement therapy or alendronate, and separate meta-analyses comparing terIParatide versus placebo or antiresorptive drugs gave similar results.

TL;DR: Sequential ABL followed by ALN appears to be an effective treatment option for postmenopausal women at risk for osteoporosis-related fractures.